Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kewei Yu

Neurology Suwanee, GA Medical Doctor

NPI 1619108354 CMS profile 4211814

3925 Johns Creek Ct Ste C2, Suwanee, GA 30024

Open in the dashboard

General payments

$4,131

78 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kewei Yu of Suwanee, GA is reported in the CMS Open Payments database as having received $4,131 across 78 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 63rd percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $637 15
2024 General $1,960 30
2023 General $383 12
2022 General $682 9
2021 General $292 5
2020 General $118 3
2019 General $58 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kewei Yu
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Kewei Yu were reported at $637. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Kewei Yu Neurology median Middle half National median
2019 $58 $474 $118–$2,177 $163
2020 $118 $367 $82–$2,309 $114
2021 $292 $438 $104–$2,547 $132
2022 $682 $442 $103–$2,388 $149
2023 $383 $464 $119–$2,312 $160
2024 $1,960 $468 $119–$2,323 $164
2025 $637 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Spinal Simplicity, LLC $1,091 14 payments
  2. AbbVie, Inc. $367 13 payments
  3. EMD Serono, Inc. $292 4 payments
  4. Eisai Inc. $241 2 payments
  5. Lundbeck LLC $181 4 payments
  6. Boston Scientific Corporation $163 7 payments
  7. Pfizer Inc. $148 7 payments
  8. Neurocrine Biosciences, Inc. $132 1 payment
  9. Alexion Pharmaceuticals, Inc. $131 1 payment
  10. Teva Pharmaceuticals USA, Inc. $131 1 payment
  11. Other $1,254 24 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,271 71 payments
  2. Travel and Lodging $772 5 payments
  3. Education $87 2 payments
Products named General payments · program years 2019–2025
  1. HA MINUTEMAN G3-R $1,091 14 payments
  2. UBRELVY $296 10 payments
  3. Leqembi $241 2 payments
  4. Mavenclad $237 2 payments
  5. QULIPTA $160 8 payments
  6. VYEPTI $143 2 payments
  7. INGREZZA $132 1 payment
  8. ULTOMIRIS $131 1 payment
  9. AUSTEDO $131 1 payment
  10. SUNOSI $130 1 payment
  11. Other $1,714 50 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

985

Median for Neurology: 833

Drug cost

$14,650

Median for Neurology: $202,670

Branded share of claims

25.1%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Sumatriptan Generic 12 $2,102
Gabapentin Generic 224 $1,988
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 81 $1,608
Pregabalin Generic 71 $1,566
Lacosamide Generic 13 $1,410
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 91 $1,012
Memantine Hcl Er Memantine Hcl Brand 11 $850
Memantine Hcl Generic 23 $646
Butalbital-Acetaminophen-Caffe Butalb/Acetaminophen/Caffeine Brand 19 $503
Cyclobenzaprine Hcl Generic 14 $410

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$178,436

Of which drugs: $2,368

Medicare patients

191

Average age 73

Services billed

4,936

117 women, 74 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 41%
Depression 35%
Ischemic heart disease 30%
Chronic kidney disease 20%
Osteoporosis 19%
Cancer 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 42 2,180 $639
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 23 172 $132
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 37 1,021 $92

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Leqembi
  • Eisai Inc. $241
$241 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $132
$132 — —
KESIMPTA
  • Novartis Pharmaceuticals Corporation $127
$127 — —
Mavenclad
  • EMD Serono, Inc. $125
$125 — —
UBRELVY
  • AbbVie, Inc. $86
$86 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

78 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record